Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Open accessAbstract
Resveratrol (RES) is a natural polyphenolic non-flavonoid compound present in grapes, mulberries, peanuts, rhubarb and in several other plants. Numerous health effects have been related with its intake, such as anti-carcinogenic, anti-inflammatory and brain protective effects. The neuroprotective effects of RES in neurological diseases, such as Alzheimer's (AD) and Parkinson's (PD) diseases, are related to the protection of neurons against oxidative damage and toxicity, and to the prevention of apoptotic neuronal death. In brain cancer, RES induces cell apoptotic death and inhibits angiogenesis and tumor invasion. Despite its great potential as therapeutic agent for the treatment of several diseases, RES exhibits some limitations. It has poor water solubility and it is chemically instable, being degraded by isomerization once exposed to high temperatures, pH changes, UV light, or certain types of enzymes. Thus, RES has low bioavailability, limiting its biological and pharmacological benefits. To overcome these limitations, RES can be delivered by nanocarriers. This field of nanomedicine studies how the drug administration, pharmacokinetics, and pharmacodynamics are affected by the use of nanosized materials. The role of nanotechnology, in the prevention and treatment of neurological diseases, arises from the necessity to mask the physicochemical properties of therapeutic drugs to prolong the half-life and to be able to cross the blood-brain barrier (BBB). This can be achieved by encapsulating the drug in a nanoparticle (NP), which can be made of different kinds of materials. An increasing trend to encapsulate and direct RES to the brain has been observed. RES has been encapsulated in many different types of nanosystems, as liposomes, lipid and polymeric NPs. Furthermore, some of these nanocarriers have been modified with targeting molecules able to recognize the brain areas. Then, this article aims to overview the RES benefits and limitations in the treatment of neurological diseases, as the different nanotechnology strategies to overcome these limitations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nano-encapsulation of resveratrol in lipid carriers or liposomes or polymeric particles could ameliorate its pharmacodynamics and pharmacokinetics.
“the nano-incapsulation in lipid carriers or liposomes as well as the insertion into polymeric particles could ameliorate both pharmacodynamics and pharmacokinetics of resveratrol (Andrade et al., 2018)”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Andrade et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED: SIRT1 Suppresses β-Amyloid Production by Activating the α-Secretase Gene ADAM10
Dönmez, G., Wang, D., Cohen, D. E., & Guarente, L. (2010) · Cell · doi:10.1016/j.cell.2010.06.020 · Cited by 433 · see citing works
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1× · see citing works
“In addition, biological barriers must be considered during the design and development of the chosen nanocarrier (Blanco et al., 2015).”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · cited 2× · see citing works
“The Aβ aggregation induces the formation of insoluble fibrils, which accumulate in senile plaques (Clippingdale et al., 2001; Selkoe, 2001; Klafki et al., 2006; Rocha et al., 2012; Loureiro et al., 2013b).”
BackgroundCancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · see citing works
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T., Mackenzie, G., Garcia-Osuna, M., Panov, A., & Greenamyre, J. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,797 · see citing works
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370 · see citing works
Yang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,262 · see citing works
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · see citing works
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053 · cited 2× · see citing works
“Mitochondrial complex I is appointed as one of the main causes of ROS production (Jenner, 2003; Henchcliffe and Beal, 2008).”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 2× · see citing works
“Posteriorly, the aggregation of oligomers forms protofibrils, which in turn form fibrils and then Aβ plaques (Walsh and Selkoe, 2007; Ahmed et al., 2010).”
BackgroundETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,394 · see citing works
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada, Y. (2004) · PubMed · Cited by 1,383 · see citing works
Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J. I., Van Nostrand, W. E., & Smith, S. O. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1799 · Cited by 1,111 · cited 1× · see citing works
“Posteriorly, the aggregation of oligomers forms protofibrils, which in turn form fibrils and then Aβ plaques (Walsh and Selkoe, 2007; Ahmed et al., 2010).”
BackgroundLiu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095 · cited 1× · see citing works
“, 2014), leading to neuroinflammation and even cell death (Liu and Hong, 2003).”
BackgroundKim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074 · see citing works
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033 · cited 1× · see citing works
“Tumor suppressor cytoplasmic protein p53 could be one of the crucial targets of RES antiproliferative activity, since most of the glioma tumors have either mutation in p53 or defects in its pathway (Rivlin et al., 2011).”
BackgroundModern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,005 · cited 3× · see citing works
“The capability of nanosystems to cross the BBB depends on their physicochemical properties, and therefore nanocarriers must meet several requirements as being non-toxic, able to carry the desired drug and able to interact with receptors present at the BBB (Chen and Liu, 2012; Masserini, 2013).”
BackgroundInfluentialAcetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949 · cited 1× · see citing works
“The scale bar corresponds to 200 nm. aggregates (Feng et al., 2009; Mishra et al., 2009; Pasinetti et al., 2015).”
BackgroundThe role of apoptosis in cancer development and treatment response
Brown, J. M., & Attardi, L. D. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1560 · Cited by 941 · see citing works
The therapeutic potential of resveratrol: a review of clinical trials
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y., & Holz, M. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0038-6 · Cited by 895 · see citing works
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869 · cited 1× · see citing works
“Also heredity and environmental factors, calcium overload, immune abnormalities and various neurotoxins could be responsible for the loss of neurons (Abou-Sleiman et al., 2006).”
BackgroundAlam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · cited 1× · see citing works
“Post-mortem brain studies genetic analysis in humans showed similar results (Alam et al., 1997; Floor and Wetzel, 1998).”
ResultLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828 · see citing works
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 786 · see citing works
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782 · see citing works
Resveratrol Promotes Clearance of Alzheimer's Disease Amyloid-β Peptides
Marambaud, P., Zhao, H., & Davies, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508246200 · Cited by 750 · cited 3× · see citing works
“Also, an in vitro experiment showed that RES reduced the Aβ secretion and Aβ fibrils accumulation (Marambaud et al., 2005).”
BackgroundTransport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715 · see citing works
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
Moussa, C., Hebron, M. L., Huang, X., Ahn, J., Rissman, R. A., Aisen, P. S. S., & Turner, R. S. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0779-0 · Cited by 712 · cited 1× · see citing works
“Tamagno et al. (2002) concluded that ROS production promotes the activation of β-secretase, stimulating the Aβ production (Murakami et al., 2005).”
BackgroundResveratrol as an anti-cancer agent: A review
Rauf, A., Imran, M., Butt, M. S., Nadeem, M., Peters, D. G., & Mubarak, M. S. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1263597 · Cited by 672 · see citing works
Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., Janle, E. M., Lobo, J., Ferruzzi, M. G., Davies, P. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.060061 · Cited by 648 · cited 2× · see citing works
“RES stimulated the AMPK activation (Vingtdeux et al., 2010; Porquet et al., 2013), which leads to the decrease of Aβ levels and extracellular Aβ accumulation (Vingtdeux et al., 2010).”
BackgroundAdministration of resveratrol: What formulation solutions to bioavailability limitations?
Amri, A., Chaumeil, J. C., Sfar, S., & Charrueau, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.083 · Cited by 622 · cited 1× · see citing works
“Nanoencapsulation will also allow decreasing RES toxicity in healthy tissues (Amri et al., 2012; Arora and Jaglan, 2017).”
BackgroundWilcock, G. K., & Esiri, M. M. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90155-1 · Cited by 608 · see citing works
Current and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2016) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 584 · see citing works
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 580 · see citing works
Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches
Cardoso, F. L., Brites, D. M. T. O., & Brito, M. A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.05.003 · Cited by 573 · see citing works
Anandatheerthavarada, H. K., Biswas, G., Robin, M.-A., & Avadhani, N. G. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207030 · Cited by 571 · cited 1× · see citing works
“In addition, Aβ-mitochondrial interactions induce oxidative stress and mitochondrial damages (Anandatheerthavarada et al., 2003).”
BackgroundNeuropathologic changes in Alzheimer's disease.
Wenk, G. L. (2003) · PubMed · Cited by 554 · see citing works
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 1× · see citing works
“The amyloid cascade hypothesis proposes that high levels of Aβ induces modifications in tau protein with consequent formation of NFTs, which causes the loss of synapses and neurons in areas related with cognitive functions such as memory (Gotz et al., 2004; Small and Duff, 2008).”
BackgroundSynaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517 · cited 1× · see citing works
“However, in recent years studies have revealed that Aβ oligomers can be more toxic than mature fibrils by inducing synaptic dysfunction, playing a key role in the development of the disease (Walsh and Selkoe, 2007; Arendt, 2009; Ballard et al., 2011).”
BackgroundOxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 506 · see citing works
Nanoparticles for Brain Drug Delivery
Masserini, M. (2013) · ISRN Biochemistry · doi:10.1155/2013/238428 · Cited by 492 · see citing works
Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H., Beal, M. F., & Gibson, G. E. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.008 · Cited by 488 · see citing works
Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats
Alam, M., & Schmidt, W. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00180-8 · Cited by 475 · cited 1× · see citing works
“This molecule is able to cross the BBB and causes neurotoxicity by mitochondrial complex-I inhibition (Alam and Schmidt, 2002; Bueler, 2009).”
BackgroundMitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 470 · see citing works
The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery
Groothuis, D. R. (2000) · Neuro-Oncology · doi:10.1093/neuonc/2.1.45 · Cited by 457 · cited 2× · see citing works
“…cells that block the path of over 98% of small-molecule drugs and 100% of large-molecule (>500 Da) (Cardoso et al., 2010), protecting the brain microenvironment from toxic substances present in the bloodstream, but allowing the transport of nutrients (Groothuis, 2000; Liebner et al., 2011).”
BackgroundFloor, E., & Wetzel, M. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010268.x · Cited by 452 · see citing works
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 446 · cited 1× · see citing works
“The PI3K/Akt/mTOR pathway is overactive in glioma tumors, resulting in reduced apoptosis and increased tumor proliferation, being frequently implicated in resistance to anticancer therapy (Burris, 2013).”
BackgroundClearance of Alzheimer's Aβ Peptide
Tanzi, R. E., Moir, R. D., & Wagner, S. L. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.024 · Cited by 431 · cited 1× · see citing works
“It is caused by the augmented mitochondrial dysfunction and oxidative stress that might occur due to the selective inhibition of complex I action (Hu et al., 2010; Tapias et al., 2014).”
BackgroundCapiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al‐Abed, Y., Davies, P., & Marambaud, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07594.x · Cited by 426 · cited 3× · see citing works
“…works demonstrated that RES inhibited the activation of microglia (Zhang et al., 2010; Capiralla et al., 2012) and astrocyte (Scuderi et al., 2014), modulating the NF-κB activity (Zhao et al., 2015; Sathya et al., 2017) and inhibiting the TLR4/NF-κB/STAT signaling cascade (Capiralla et al., 2012).”
BackgroundNeuroprotective action of resveratrol
Bastianetto, S., Ménard, C., & Quirion, R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.011 · Cited by 411 · see citing works
Anticancer Molecular Mechanisms of Resveratrol
Varoni, E. M., Faro, A. F. L., Sharifi‐Rad, J., & Iriti, M. (2016) · Frontiers in Nutrition · doi:10.3389/fnut.2016.00008 · Cited by 402 · see citing works
Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death
Jang, J.-H. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00062-5 · Cited by 391 · cited 2× · see citing works
“Some authors observed that RES has protective activity in PC12 cells through the prevention of NF-κB activation, inhibiting the apoptosis (Jang and Surh, 2003; Seo et al., 2018).”
BackgroundOxidative stress increases expression and activity of BACE in NT2 neurons
Tamagno, E., Bardini, P., Obbili, A., Vitali, A., Borghi, R., Zaccheo, D., Pronzato, M. A., Danni, O., Smith, M. A., Perry, G., et al. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0515 · Cited by 385 · cited 1× · see citing works
“Tamagno et al. (2002) concluded that ROS production promotes the activation of β-secretase, stimulating the Aβ production (Murakami et al., 2005).”
BackgroundNeuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats
Jin, F. J., Wu, Q., Lu, Y., Gong, Q., & Shi, J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.005 · Cited by 384 · see citing works
MMP ‐9 in translation: from molecule to brain physiology, pathology, and therapy
Vafadari, B., Salamian, A., & Kaczmarek, L. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13415 · Cited by 381 · see citing works
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370 · see citing works
Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models
Hu, L., Lu, M., Tiong, C. X., Dawe, G. S., Hu, G., & Bian, J. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00543.x · Cited by 365 · see citing works
Therapeutic approaches to Alzheimer's disease
Klafki, H., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 359 · see citing works
Insights into Direct Nose to Brain Delivery: Current Status and Future Perspective
Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838713 · Cited by 359 · cited 1× · see citing works
“This molecule increases the expression of some antioxidant enzymes in the brain of healthful animals and presents an excellent antioxidant effect (Mokni et al., 2007).”
BackgroundLoureiro, J. A., Andrade, S., Duarte, A., Neves, A. R., Queiroz, J. F., Nunes, C., Sevin, E., Fénart, L., Gosselet, F., Coelho, M. A. N., et al. (2017) · Molecules · doi:10.3390/molecules22020277 · Cited by 342 · cited 2× · see citing works
“Evidences showed that RES delays or even inhibits the Aβ aggregation (Feng et al., 2009; Andrade et al., 2015; Loureiro et al., 2017).”
BackgroundResveratrol—A boon for treating Alzheimer's disease?
Anekonda, T. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.004 · Cited by 341 · cited 1× · see citing works
“Thus, creating a vicious cycle, where ROS promote Aβ production, which in turn, promotes ROS production (Anekonda, 2006; Li et al., 2012).”
BackgroundPathogenesis of Parkinson's disease
Hirsch, E. C., Jenner, P., & Przedborski, S. (2013) · Movement Disorders · doi:10.1002/mds.25032 · Cited by 336 · see citing works
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease
Büeler, H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.006 · Cited by 326 · cited 1× · see citing works
“This molecule is able to cross the BBB and causes neurotoxicity by mitochondrial complex-I inhibition (Alam and Schmidt, 2002; Bueler, 2009).”
BackgroundResveratrol nanoformulations: Challenges and opportunities
Summerlin, N., Soo, E., Thakur, S. S., Qu, Z., Jambhrunkar, S., & Popat, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.003 · Cited by 319 · see citing works
Neves, A. R., Lúcio, M., Lima, J. L. F. C., & Reis, S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799945085 · Cited by 315 · see citing works
Bastianetto, S., Zheng, W., & Quirion, R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703626 · Cited by 302 · see citing works
Ladiwala, A. R. A., Lin, J. C., Bale, S. S., Marcelino, A. M. C., Bhattacharya, M., Dordick, J. S., & Tessier, P. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.133108 · Cited by 299 · cited 2× · see citing works
“Also, RES converted toxic species such as oligomers, protofibrils, and fibrils into non-toxic aggregated (Ladiwala et al., 2010; Rushworth et al., 2013).”
BackgroundNovel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bézard, E., Brotchie, J. M., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, É. C., Jenner, P. G., Novère, N. G. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 299 · see citing works
Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma
Jhaveri, A. M., Deshpande, P. P., Pattni, B. S., & Torchilin, V. P. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.006 · Cited by 298 · see citing works
Vingtdeux, V., Davies, P., Dickson, D. W., & Marambaud, P. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0759-x · Cited by 297 · see citing works
Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation
Feng, Y. N., Wang, X., Yang, S., Wang, Y., Zhang, X., Du, X., Sun, X., Zhao, M., Huang, L., & Liu, R. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 297 · see citing works
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Bhowmik, A., Khan, R., & Ghosh, M. K. (2015) · BioMed Research International · doi:10.1155/2015/320941 · Cited by 293 · see citing works
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction
Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., Sosunov, A., McKhann, G., Funatsu, Y., Nakamichi, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905686106 · Cited by 290 · cited 1× · see citing works
“RAGE is a receptor of the immunoglobulin super family that is found in BBB and that is responsible for the Aβ transport, from the blood to the brain, leading to mitochondrial dysfunction (Takuma et al., 2009).”
BackgroundAre mitochondria critical in the pathogenesis of Alzheimer's disease?
Reddy, P. H., & Beal, M. F. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.03.004 · Cited by 289 · see citing works
A comprehensive review of the health perspectives of resveratrol
Rauf, A., Imran, M., Suleria, H. A. R., Ahmad, B., Peters, D. G., & Mubarak, M. S. (2017) · Food & Function · doi:10.1039/c7fo01300k · Cited by 286 · see citing works
Nanoparticle Technology for Delivery of Drugs Across the Blood–Brain Barrier
Schröeder, U., Sommerfeld, P., Ulrich, S., & Sabel, B. A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980084y · Cited by 275 · see citing works
The Sirtuin family: therapeutic targets to treat diseases of aging
Milne, J. C., & Denu, J. M. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.019 · Cited by 271 · see citing works
Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8
Porquet, D., Casadesús, G., Bayod, S., Vicente, A., Canudas, A. M., Vilaplana, J., Pelegrı́, C., Sanfeliu, C., Camins, A., Pallàs, M., et al. (2012) · AGE · doi:10.1007/s11357-012-9489-4 · Cited by 268 · cited 2× · see citing works
“RES stimulated the AMPK activation (Vingtdeux et al., 2010; Porquet et al., 2013), which leads to the decrease of Aβ levels and extracellular Aβ accumulation (Vingtdeux et al., 2010).”
BackgroundChen, M., Yi, L., Jin, X., Liang, X., Zhou, Y. G., Zhang, T., Xie, Q., Zhou, X., Chang, H., Fu, Y., et al. (2013) · Autophagy · doi:10.4161/auto.26336 · Cited by 267 · see citing works
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
Seo, E.-J., Fischer, N., & Efferth, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.030 · Cited by 265 · cited 1× · see citing works
“Some authors observed that RES has protective activity in PC12 cells through the prevention of NF-κB activation, inhibiting the apoptosis (Jang and Surh, 2003; Seo et al., 2018).”
BackgroundAlbani, D., Polito, L., Batelli, S., Mauro, S. D., Fracasso, C., Martelli, G., Colombo, L., Manzoni, C., Salmona, M., Caccia, S., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06228.x · Cited by 260 · cited 1× · see citing works
“An in vitro study suggested that RES protected SK-N-BE cells against the oxidative stress and toxicity produced by Aβ, through the SIRT1 activation that inhibited the hydrogen peroxide production (Albani et al., 2009).”
BackgroundNeurobiology and treatment of Parkinson's disease
Schapira, A. H. V. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.005 · Cited by 252 · cited 1× · see citing works
“After AD, PD is the most common neurodegenerative disorder that causes motor impairment on the middle-aged or elderly population (Schapira, 2009).”
BackgroundNeurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251 · cited 1× · see citing works
“Some causes are pointed for the deficient Aβ elimination including the increase of aggregation and difficulty to remove Aβ through the BBB (Mawuenyega et al., 2010; Sagare et al., 2012).”
BackgroundBates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247 · cited 1× · see citing works
“The augmented levels of Aβ peptide found in the brain are a consequence of the overproduction and/or the reduced clearance of Aβ (Bates et al., 2009).”
BackgroundNeuroprotective effects of resveratrol in Alzheimer disease pathology
Rege, S. D., Geetha, T., Griffin, G. D., Broderick, T. L., & Babu, J. R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00218 · Cited by 243 · see citing works
Neves, A. R., Queiroz, J. F., & Reis, S. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0177-x · Cited by 241 · cited 1× · see citing works
“Similar to the case of AD, RES acts mainly by inhibiting ROS produced by hippocampal cells to reduce cell death, by activating AMPK (Bastianetto et al., 2000; Virgili and Contestabile, 2000; Nicolini et al., 2001; Lee et al., 2007).”
BackgroundPasinetti, G. M., Wang, J., Ho, L., Zhao, W., & Dubner, L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.006 · Cited by 238 · see citing works
Jose, S., Anju, S. S., Cinu, T. A., Aleykutty, N., Thomas, S., & Souto, E. B. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.003 · Cited by 237 · see citing works
Virgili, M., & Contestabile, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00820-x · Cited by 234 · see citing works
Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Li, F., Gong, Q., Dong, H., & Shi, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212798919075 · Cited by 231 · see citing works
Current concepts of blood-brain barrier development
Liebner, S., Czupalla, C. J., & Wolburg, H. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.103224sl · Cited by 227 · see citing works
Lin, C., Lee, C.-C., Shih, Y., Lin, T.-Y., Wang, S.-H., Lin, Y., & Shih, C.-M. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.487 · Cited by 225 · cited 1× · see citing works
“Several other authors showed that RES enhanced chemosensitization of glioma cells to temozolomide activity, by altering multiple signaling pathways and promoting apoptosis (Lin et al., 2012; Yuan et al., 2012; Li et al., 2016) and cell cycle arrest (Filippi-Chiela et al.”
BackgroundTherapeutic potential of resveratrol in Alzheimer's disease
Vingtdeux, V., Dreses‐Werringloer, U., Zhao, H., Davies, P. J., & Marambaud, P. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s6 · Cited by 224 · see citing works
Small-Molecule Allosteric Activators of Sirtuins
Sinclair, D. A., & Guarente, L. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134657 · Cited by 223 · see citing works
Huang, T.-C., Lu, K., Wo, Y.-Y. P., Wu, Y.-J., & Yang, Y.-L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029102 · Cited by 217 · cited 1× · see citing works
“Among these molecules are ROS, interleukins, nitric oxide (Kim et al., 2006; Huang et al., 2011), monocyte chemoattractant protein-1 and prostaglandin E2 (Kim et al., 2006).”
BackgroundResveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats
Tseng, S.-H., Lin, S.-M., Chen, J.-C., Su, Y., Huang, H., Chen, C.-K., Lin, P.-Y., & Chen, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0105 · Cited by 217 · see citing works
Nano carriers for drug transport across the blood–brain barrier
Li, X.-M., Tsibouklis, J., Weng, T., Zhang, B.-N., Yin, G.-Q., Feng, G.-Z., Cui, Y.-D., Savina, I., Mikhalovska, L., Sandeman, S., et al. (2017) · Journal of drug targeting (Print) · doi:10.1080/1061186x.2016.1184272 · Cited by 217 · cited 1× · see citing works
“The modifications strategies can be based on attaching to the nanomaterial surface different moieties that improve the recognition of the nanoparticle (NP) by the BBB receptors (Loureiro et al., 2015b, 2016; Li et al., 2017).”
BackgroundWang, H., Jiang, T., Li, W., Gao, N., & Zhang, T. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.10.021 · Cited by 214 · see citing works
Effect of Resveratrol on Antioxidant Enzyme Activities in the Brain of Healthy Rat
Mokni, M., Elkahoui, S., Limam, F., Amri, M., & Aouani, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9255-z · Cited by 213 · cited 3× · see citing works
“Several studies described RES as a strong anti-inflammatory molecule (Chen et al., 2013; Moussa et al., 2017).”
BackgroundChemistry, Stability and Bioavailability of Resveratrol
Francioso, A., Mastromarino, P., Masci, A., D’Erme, M., & Mosca, L. (2014) · Medicinal Chemistry · doi:10.2174/15734064113096660053 · Cited by 208 · see citing works
Alzheimer's disease drug development and the problem of the blood‐brain barrier
Pardridge, W. M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.06.003 · Cited by 203 · cited 1× · see citing works
“Thus, BBB hinders the development of novel therapies for brain disorders (Pardridge, 2009; Loureiro et al., 2014b; Bhowmik et al., 2015).”
BackgroundTau protein, the paired helical filament and Alzheimer's disease
Goedert, M., Klug, A., & Crowther, R. A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s323 · Cited by 195 · see citing works
Tau oligomers and aggregation in Alzheimer’s disease
Meraz‐Ríos, M. A., León, K. I. L.-D., Campos‐Peña, V., Anda-Hernández, M. A. D., & Mena‐López, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06511.x · Cited by 193 · see citing works
Resveratrol-loaded polymeric micelles protect cells from Aβ-induced oxidative stress
Lu, X., Ji, C., Xu, H., Li, X., Ding, H., Ye, M., Zhu, Z., Ding, D., Jiang, X., Ding, X., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.03.021 · Cited by 193 · cited 2× · see citing works
“Therefore, this nanosystem seems to have a great potential as therapeutic method to treat AD (Lu et al., 2009).”
BackgroundPangeni, R., Sharma, S., Mustafa, G., Ali, J., & Baboota, S. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/48/485102 · Cited by 192 · see citing works
Zhang, F., Shi, J., Zhou, H., Wilson, B. C., Hong, J., & Gao, H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064535 · Cited by 189 · cited 3× · see citing works
“Numerous in vitro and in vivo works demonstrated that RES inhibited the activation of microglia (Zhang et al., 2010; Capiralla et al., 2012) and astrocyte (Scuderi et al., 2014), modulating the NF-κB activity (Zhao et al., 2015; Sathya et al., 2017) and inhibiting the TLR4/NF-κB/STAT signaling…”
BackgroundRed Wine Ingredient Resveratrol Protects from β-Amyloid Neurotoxicity
Savaskan, E., Olivieri, G., Meier, F., Seifritz, E., Wirz‐Justice, A., & Müller-Spahn, F. (2003) · Gerontology · doi:10.1159/000073766 · Cited by 182 · see citing works
Filippi‐Chiela, E. C., Villodre, E. S., Zamin, L. L., & Lenz, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020849 · Cited by 181 · see citing works
Resveratrol differentially modulates inflammatory responses of microglia and astrocytes
Lu, X., Ma, L., Ruan, L., Kong, Y., Mou, H., Zhang, Z., Wang, Z., Wang, J., & Le, Y. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-46 · Cited by 180 · cited 2× · see citing works
“Numerous studies showed that RES inhibited the secretion and activity of several cytokines and molecules with inflammatory activity (Lu et al., 2010; Zhang et al., 2010).”
BackgroundResveratrol and Alzheimer’s Disease: Mechanistic Insights
Ahmed, T., Javed, S., Javed, S., Tariq, A., Šamec, D., Tejada, S., Nabavi, S. F., Braidy, N., & Nabavi, S. M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9839-9 · Cited by 179 · cited 3× · see citing works
“, 2012), which in turn favors the connection between nuclear factor kappa B (NFκB) and specific regions of DNA, that promotes cell and tissue injuries leading to cell death (Draczynska-Lusiak et al., 1998; Ahmed et al., 2017).”
BackgroundLoureiro, J. A., Gomes, B., Fricker, G., Coelho, M. A. N., Rocha, S., & Pereira, M. D. C. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.04.041 · Cited by 179 · see citing works
Neuroprotective Role of Trans-Resveratrol in a Murine Model of Familial Alzheimer's Disease
Porquet, D., Griñán‐Ferré, C., Ferrer, I., Camins, A., Sanfeliu, C., del Valle, J., & Pallàs, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140444 · Cited by 178 · see citing works
Shao, J., Li, X., Lu, X., Chen, J., Hu, Y., Li, Q., You, Y., & Fu, Z. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.03.010 · Cited by 173 · cited 1× · see citing works
“Recent studies show that RES can promote caspase3 activation by inhibiting the PI3K/Akt/mTOR intracellular signaling pathway in glioma cells (Jiang et al., 2009a,b).”
BackgroundResveratrol: A Focus on Several Neurodegenerative Diseases
Tellone, E., Galtieri, A., Russo, A., Giardina, B., & Ficarra, S. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/392169 · Cited by 172 · see citing works
Frozza, R. L., Bernardi, A., Paese, K., Hoppe, J. B., da Silva, T., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. G. (2010) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2010.1161 · Cited by 172 · see citing works
The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery
Groothuis, D. R. (2000) · Neuro-Oncology · doi:10.1215/s1522851799000307 · Cited by 168 · see citing works
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165 · see citing works
Li, X., Zhao, Y. L., Sun, M., Shi, J., Ju, R.-J., Zhang, C.-X., Li, X., Zhao, W., Mu, L.-M., Zeng, F., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.049 · Cited by 163 · cited 1× · see citing works
“in the last decade for glioma tumors’ therapy with several different drugs and nanomaterials (Li et al., 2014; Householder et al., 2015; Yao et al., 2015; Ramalho et al., 2018b).”
BackgroundOxidative Stress and Microglial Cells in Parkinson's Disease
Peterson, L. J., & Flood, P. M. (2012) · Mediators of Inflammation · doi:10.1155/2012/401264 · Cited by 161 · see citing works
Murakami, K., Irie, K., Ohigashi, H., Hara, H., Nagao, M., Shimizu, T., & Shirasawa, T. (2005) · Journal of the American Chemical Society · doi:10.1021/ja054041c · Cited by 161 · cited 1× · see citing works
“RES also inhibits the ribonucleotide reductase required for the DNA synthesis at the S-phase of the cell cycle, resulting in the cell cycle arrest (Neves et al., 2012).”
BackgroundHao, J., Zhao, J., Zhang, S., Tong, T., Zhuang, Q., Jin, K., Chen, W., & Tang, H. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.08.011 · Cited by 160 · see citing works
Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation
Haque, S., Md, S., Fazil, M., Kumar, M., Sahni, J. K., Ali, J., & Baboota, S. (2012) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.02.051 · Cited by 158 · see citing works
Feng, X., Liang, N., Zhu, D., Gao, Q., Peng, L., Dong, H., Yue, Q., Liu, H., Bao, L., Zhang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059888 · Cited by 158 · cited 2× · see citing works
“…of binding to the N-terminal of SIRT1 increasing their activity (Milne and Denu, 2008; Feng et al., 2013), decreasing Aβ accumulation (Kim et al., 2007; Feng et al., 2013), protecting against neurotoxicity (Porquet et al., 2013) and cell death (Sinclair and Guarente, 2014; Sathya et al., 2017).”
BackgroundResveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.
Jiang, H., Shang, X., Wu, H., Gautam, S. C., Al‐Holou, S. N., Li, C., Kuo, J., Zhang, L., & Chopp, M. (2009) · PubMed · Cited by 154 · see citing works
Rushworth, J. V., Jarosz-Griffiths, H., Watt, N. T., & Hooper, N. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400358 · Cited by 151 · cited 1× · see citing works
“Also, RES converted toxic species such as oligomers, protofibrils, and fibrils into non-toxic aggregated (Ladiwala et al., 2010; Rushworth et al., 2013).”
BackgroundShen, Y., Cao, B., Snyder, N. R., Woeppel, K. M., Eles, J. R., & Cui, X. T. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0340-7 · Cited by 149 · see citing works
Kumar, A., Naidu, P. S., Seghal, N., & Padi, S. S. V. (2006) · Pharmacology · doi:10.1159/000097511 · Cited by 147 · see citing works
Resveratrol as a Therapeutic Agent for Alzheimer’s Disease
Ma, T., Tan, M., Yu, J., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/350516 · Cited by 144 · cited 1× · see citing works
“, 2007), which promote the Aβ production (Ma et al., 2014), leading to neuroinflammation and even cell death (Liu and Hong, 2003).”
BackgroundTau-Based Treatment Strategies in Neurodegenerative Diseases
Schneider, A., & Mandelkow�, E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.006 · Cited by 142 · see citing works
Götz, J., Schild, A., Hoerndli, F. J., & Pennanen, L. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.07.013 · Cited by 141 · see citing works
Pardeshi, C. V., Rajput, P. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Drug Delivery · doi:10.3109/10717544.2012.752421 · Cited by 141 · see citing works
Yang, Y., Chang, Y., Huang, P., Chiou, G., Tseng, L., Chiou, S., Chen, M., Chen, M., Shih, Y., Chang, C., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22806 · Cited by 139 · see citing works
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment
Ramalho, M. J., Sevin, E., Gosselet, F., Lima, J. P., Coelho, M. A. N., Loureiro, J. A., & Pereira, M. D. C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.04.062 · Cited by 139 · see citing works
Enhanced Protein Kinase C Activity Correlates with the Growth Rate of Malignant Gliomas in Vitro
Couldwell, W. T., Uhm, J. H., Antel, J. P., & Yong, V. W. (1991) · Neurosurgery · doi:10.1097/00006123-199112000-00013 · Cited by 137 · see citing works
Neuroprotective effects of resveratrol against traumatic brain injury in immature rats
Sönmez, Ü., Sönmez, A., Erbil, G., Tekmen, I., & Baykara, B. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.04.070 · Cited by 135 · see citing works
Inhibiting Islet Amyloid Polypeptide Fibril Formation by the Red Wine Compound Resveratrol
Mishra, R., Sellin, D., Radovan, D., Gohlke, A., & Winter, R. (2009) · ChemBioChem · doi:10.1002/cbic.200800762 · Cited by 134 · cited 1× · see citing works
“Furthermore, this route is noninvasive and it is an alternative route that effectively bypasses the BBB, circumventing significant intestinal and hepatic metabolism (Haque et al., 2012; Mittal et al., 2014).”
BackgroundSaravanan, K. S., Madathil, S. K., & Mohanakumar, K. P. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.051 · Cited by 134 · see citing works
Resveratrol-induced apoptotic death in human U251 glioma cells
Jiang, H., Zhang, L., Kuo, J., Kuo, K., Gautam, S. C., Groc, L., Rodríguez, A. I., Koubi, D., Hunter, T. J., Corcoran, G. B., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0056 · Cited by 134 · see citing works
Zhao, H., Li, N., Wang, Q.-N., Cheng, X., Li, X. M., & Liu, T. T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.10.006 · Cited by 131 · cited 6× · see citing works
“…works demonstrated that RES inhibited the activation of microglia (Zhang et al., 2010; Capiralla et al., 2012) and astrocyte (Scuderi et al., 2014), modulating the NF-κB activity (Zhao et al., 2015; Sathya et al., 2017) and inhibiting the TLR4/NF-κB/STAT signaling cascade (Capiralla et al., 2012).”
BackgroundInfluentialYuan, Y., Xue, X., Guo, R., Sun, X., & Hu, G. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00319.x · Cited by 130 · cited 2× · see citing works
“Several other authors showed that RES enhanced chemosensitization of glioma cells to temozolomide activity, by altering multiple signaling pathways and promoting apoptosis (Lin et al., 2012; Yuan et al., 2012; Li et al., 2016) and cell cycle arrest (Filippi-Chiela et al., 2013).”
BackgroundWang, Y., Xu, H., Fu, Q., Ma, R., & Xiang, J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.02.025 · Cited by 129 · see citing works
Householder, K. T., DiPerna, D. M., Chung, E. P., Wohlleb, G. M., Dhruv, H., Berens, M. E., & Sirianni, R. W. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.002 · Cited by 129 · see citing works
Carneiro, P., Loureiro, J. A., Delerue-Matos, C. M., Morais, S., & Pereira, M. D. C. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.07.181 · Cited by 128 · see citing works
Lindner, G. D. R., Santos, D. B., Colle, D., Moreira, E. L. G., Prediger, R. D., Farina, M., Khalil, N. M., & Mainardes, R. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.165 · Cited by 126 · see citing works
Transferrin modified PEG-PLA-resveratrol conjugates: In vitro and in vivo studies for glioma
Guo, W., Li, A., Jia, Z., Yuan, Y., Dai, H., & Hong-xiu, L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.034 · Cited by 122 · see citing works
Vijayakumar, M. R., Vajanthri, K. Y., Balavigneswaran, C. K., Mahto, S. K., Mishra, N., Muthu, M. S., & Singh, S. K. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.05.037 · Cited by 122 · see citing works
Abolfathi, A. A., Mohajeri, D., Rezaie, A. R., & Nazeri, M. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/740671 · Cited by 120 · cited 1× · see citing works
“This causes lipid oxidation, decrease of membrane integrity and augmented permeability to Ca2+ in plasma membrane (Abolfathi et al., 2012; Li et al., 2012), which in turn favors the connection between nuclear factor kappa B (NFκB) and specific regions of DNA, that promotes cell and tissue injuries leading to cell deat…”
BackgroundFilippi‐Chiela, E. C., Thomé, M. P. M., Silva, M. M. B. E., Pelegrini, A. L., Ledur, P. F., Garicochea, B., Zamin, L. L., & Lenz, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-147 · Cited by 115 · see citing works
Enhanced Protein Kinase C Activity Correlates with the Growth Rate of Malignant Gliomas in Vitro
Couldwell, W. T., Uhm, J. H., Antel, J. P., et al. (1991) · Neurosurgery · doi:10.1227/00006123-199112000-00013 · Cited by 114 · see citing works
Pehlivan, S. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1156-7 · Cited by 113 · see citing works
Yao, H., Wang, K., Wang, Y., Wang, S., Li, J., Lou, J., Ye, L., Yan, X., Lu, W., & Huang, R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.034 · Cited by 109 · see citing works
Resveratrol-Loaded Lipid-Core Nanocapsules Treatment Reduces In Vitro and In Vivo Glioma Growth
Figueiró, F., Bernardi, A., Frozza, R. L., Terroso, T. F., Zanotto‐Filho, A., Jandrey, E. H. F., Moreira, J. C. F., Salbego, C. G., Edelweiss, M. I. A., Pohlmann, A. R., et al. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1547 · Cited by 109 · see citing works
The binding of resveratrol to monomer and fibril amyloid beta
Ge, J., Qiao, J., Qi, C., Wang, C.-W., & Zhou, J. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.012 · Cited by 105 · see citing works
Clark, P. A., Bhattacharya, S., Elmayan, A., Darjatmoko, S. R., Thuro, B. A., Yan, M. B., van Ginkel, P. R., Polans, A. S., & Kuo, J. S. (2016) · Journal of neurosurgery · doi:10.3171/2016.1.jns152077 · Cited by 105 · see citing works
Kwon, K. J., Kim, J. N., Kim, M. K., Lee, J., Ignarro, L. J., Kim, H., Shin, C. Y., & Han, S. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00820.x · Cited by 99 · see citing works
Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine
Lee, M. K., Kang, S. J., Poncz, M., Song, K., & Park, K. S. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.42 · Cited by 99 · cited 1× · see citing works
“Similar to the case of AD, RES acts mainly by inhibiting ROS produced by hippocampal cells to reduce cell death, by activating AMPK (Bastianetto et al., 2000; Virgili and Contestabile, 2000; Nicolini et al., 2001; Lee et al., 2007).”
BackgroundThe amyloid‐β peptide and its role in Alzheimer's disease
Clippingdale, A. B., Wade, J. D., & Barrow, C. J. (2001) · Journal of Peptide Science · doi:10.1002/psc.324 · Cited by 97 · cited 1× · see citing works
“The Aβ aggregation induces the formation of insoluble fibrils, which accumulate in senile plaques (Clippingdale et al., 2001; Selkoe, 2001; Klafki et al., 2006; Rocha et al., 2012; Loureiro et al., 2013b).”
BackgroundTargeting Nanoparticles Across The Blood–Brain Barrier with Monoclonal Antibodies
Loureiro, J. A., Gomes, B., Coelho, M. A. N., Pereira, M. D. C., & Rocha, S. (2014) · Nanomedicine · doi:10.2217/nnm.14.27 · Cited by 97 · see citing works
Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease
Tapias, V., Cannon, J. R., & Greenamyre, J. T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.077 · Cited by 97 · see citing works
Resveratrol and Alzheimer’s disease: message in a bottle on red wine and cognition
Granzotto, A., & Zatta, P. F. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00095 · Cited by 96 · cited 4× · see citing works
“Also, RES reduced the Aβ production (Pasinetti et al., 2015) through the activation of SIRT1 that activate the α-secretase (Donmez et al., 2010; Granzotto and Zatta, 2014) and the reduction of the activity of β-secretase (Jeon et al., 2007; Porquet et al., 2014).”
BackgroundInfluentialPardeshi, C. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-013-4965-7 · Cited by 95 · see citing works
Zhang, X. (2012) · Oncology Reports · doi:10.3892/or.2012.1715 · Cited by 95 · cited 1× · see citing works
“Several other authors showed that RES enhanced chemosensitization of glioma cells to temozolomide activity, by altering multiple signaling pathways and promoting apoptosis (Lin et al., 2012; Yuan et al., 2012; Li et al., 2016) and cell cycle arrest (Filippi-Chiela et al., 2013).”
Backgroundde Almeida, L. M. V., Piñeiro, C. C., Leite, M. C., Brolese, G., Tramontina, F. F., Feóli, A. M. P., Gottfried, C., & Gonçalves, C. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9152-2 · Cited by 95 · see citing works
Wang, G., Dai, F., Yu, K., Jia, Z., Zhang, A., Huang, Q., Kang, C., Jiang, H., & Pu, P. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2863 · Cited by 93 · see citing works
He, X., Li, Z., Rizak, J. D., Wu, S., Wang, Z., He, R., Su, M., Qin, D., Wang, J., & Hu, X. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00598 · Cited by 93 · cited 4× · see citing works
“RES is a stimulator of PP2A activity reducing tau phosphorylation (Schweiger et al., 2017).”
BackgroundInfluentialResveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex
Schweiger, S., Matthes, F., Posey, K. L., Kickstein, E., Weber, S. S., Hettich, M. M., Pfurtscheller, S., Ehninger, D., Schneider, R., & Krauß, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-12974-4 · Cited by 92 · cited 1× · see citing works
“RES is a stimulator of PP2A activity reducing tau phosphorylation (Schweiger et al., 2017).”
BackgroundNicolini, G., Rigolio, R., Miloso, M., Bertelli, A. A. E., & Tredici, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01654-8 · Cited by 90 · see citing works
Kim, Y., Lim, S., Rhee, S., Park, K., Kim, C., Choi, B., Lee, S. J., Park, Y., & Choi, Y. H. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.6.1069 · Cited by 88 · cited 1× · see citing works
“Among these molecules are ROS, interleukins, nitric oxide (Kim et al., 2006; Huang et al., 2011), monocyte chemoattractant protein-1 and prostaglandin E2 (Kim et al., 2006).”
BackgroundNanobiotechnology and its applications in drug delivery system: a review
Khan, I., Khan, M., Umar, M. N., & Oh, D. (2015) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2014.0062 · Cited by 87 · see citing works
Palle, S., & Neerati, P. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1474-8 · Cited by 87 · cited 4× · see citing works
“Pangeni et al., 2014 Increase of the glutathione and superoxide dismutase levels and decrease of the malondialdehyde level.”
BackgroundMethodInfluentialBrain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles
Trotta, V., Pavan, B., Ferraro, L., Beggiato, S., Traini, D., dos Reis, L. G., Scalia, S., & Dalpiaz, A. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.02.010 · Cited by 86 · see citing works
Capping of Aβ42 Oligomers by Small Molecule Inhibitors
Fu, Z., Aucoin, D., Ahmed, M., Ziliox, M., Nostrand, W. E. V., & Smith, S. O. (2014) · Biochemistry · doi:10.1021/bi500910b · Cited by 85 · cited 1× · see citing works
“As observed in Figure 3 the formation of amyloid fibrils was prevented with RES treatment, through the binding of RES to the N-terminus of Aβ monomers (Fu et al., 2014).”
BackgroundAmyloid Clearance as a Treatment Target Against Alzheimer's Disease
Kurz, A., & Perneczky, R. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102139 · Cited by 83 · cited 3× · see citing works
“The imbalance between Aβ production and the elimination of the peptide leads to the progress of AD (Kurz and Perneczky, 2011).”
BackgroundDrug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.019 · Cited by 83 · see citing works
Properties and molecular mechanisms of resveratrol: a review
Yang, T., Wang, L., Zhu, M., Zhang, L., & Yan, L. (2015) · Die Pharmazie · doi:10.31083/ph.2015.5571 · Cited by 83 · cited 1× · see citing works
“Recent studies showed that RES inhibits VEGF expression and activity in glioma cells, suppressing angiogenesis (Tseng et al., 2004; Wang et al., 2015).”
Backgroundβ-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma
Jeon, S. Y., Kwon, S.-H., Seong, Y. H., Bae, K., Hur, J.-M., Lee, Y.-Y., Suh, D., & Song, K. S. (2006) · Phytomedicine · doi:10.1016/j.phymed.2006.09.003 · Cited by 81 · cited 1× · see citing works
“Also, RES reduced the Aβ production (Pasinetti et al., 2015) through the activation of SIRT1 that activate the α-secretase (Donmez et al., 2010; Granzotto and Zatta, 2014) and the reduction of the activity of β-secretase (Jeon et al., 2007; Porquet et al., 2014).”
BackgroundVijayakumar, M. R., Kumari, L., Patel, K. K., Vuddanda, P. R., Vajanthri, K. Y., Mahto, S. K., & Singh, S. K. (2016) · RSC Advances · doi:10.1039/c6ra10777j · Cited by 80 · see citing works
Zeng, W., Zhang, W., Lu, F., Gao, L., & Gao, G. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.054 · Cited by 80 · see citing works
Anticonvulsant activity of resveratrol-loaded liposomes in vivo
Ethemoglu, M. S., Şeker, F. B., Akkaya, H., Kılıç, E., Aslan, İ., Erdogan, C. S., & Yılmaz, B. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.026 · Cited by 74 · see citing works
Oxidized lipoproteins activate NF-κB binding activity and apoptosis in PC12 cells
Draczynska‐Lusiak, B., Chen, Y. M., & Sun, A. Y. (1998) · Neuroreport · doi:10.1097/00001756-199802160-00028 · Cited by 72 · cited 1× · see citing works
“…to Ca2+ in plasma membrane (Abolfathi et al., 2012; Li et al., 2012), which in turn favors the connection between nuclear factor kappa B (NFκB) and specific regions of DNA, that promotes cell and tissue injuries leading to cell death (Draczynska-Lusiak et al., 1998; Ahmed et al., 2017).”
BackgroundLipid-Core Nanocapsules Improve the Effects of Resveratrol Against Aβ-Induced Neuroinflammation
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. G. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1709 · Cited by 70 · see citing works
Rege, S. D., Geetha, T., Broderick, T. L., & Babu, J. R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150204130009 · Cited by 69 · cited 1× · see citing works
“Additionally, RES decreased the lipid peroxide levels in H19-7 cells exposed to Aβ (Rege et al., 2015), inhibited membrane lipid peroxidation and decreased the toxic effects produced by ROS (Vingtdeux et al., 2008; Rege et al., 2015).”
BackgroundCurcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons
Patil, S. P., Tran, N. T., Geekiyanage, H., Liu, L., & Chan, C. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.008 · Cited by 68 · cited 1× · see citing works
“This reduction can be associated with the ability of RES to upregulate BAG2 levels, an endogenous protein responsible for removing the accumulated tau (Patil et al., 2013).”
BackgroundSirtuin modulators control reactive gliosis in an in vitro model of Alzheimer’s disease
Scuderi, C., Stecca, C., Bronzuoli, M. R., Rotili, D., Valente, S., Mai, A., & Steardo, L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00089 · Cited by 68 · see citing works
Combination Treatment with Resveratrol and Sulforaphane Induces Apoptosis in Human U251 Glioma Cells
Jiang, H., Shang, X., Wu, H., Huang, G., Wang, Y., Al‐Holou, S. N., Gautam, S. C., & Chopp, M. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0040-7 · Cited by 67 · see citing works
Jhang, K. A., Park, J., Kim, H.-S., & Chong, Y. H. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b03252 · Cited by 67 · cited 1× · see citing works
“Another study concluded that the ability of RES to protect against tau hyperphosphorylation and to stimulate the dephosphorylation of tau protein, is related with the inhibition of GSK-3β and CaMKII and the activation of protein phosphatase 2 (PP2A) (He et al., 2017; Jhang et al., 2017).”
BackgroundNutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer’s disease
Sadhukhan, P., Saha, S., Dutta, S., Mahalanobish, S., & Sil, P. C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.028 · Cited by 66 · see citing works
Dual ligand immunoliposomes for drug delivery to the brain
Loureiro, J. A., Gomes, B., Fricker, G., Cardoso, I., Ribeiro, C. A., Gaiteiro, C., Coelho, M. A. N., Pereira, M. D. C., & Rocha, S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.06.067 · Cited by 64 · see citing works
PLGA nanoparticles as a platform for vitamin D-based cancer therapy
Ramalho, M. J., Loureiro, J. A., Gomes, B., Frasco, M. F., Coelho, M. A. N., & Pereira, M. D. C. (2015) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.6.135 · Cited by 62 · see citing works
Saha, A., Sarkar, C., SINGH, S. P., Zhang, Z., Munasinghe, J., Peng, S., Chandra, G., Kong, E., & Mukherjee, A. B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds038 · Cited by 62 · see citing works
Hayashibara, T., Yamada, Y., Nakayama, S., Harasawa, H., Tsuruda, K., Sugahara, K., Miyanishi, T., Kamihira, S., Tomonaga, M., & Maita, T. (2002) · Nutrition and Cancer · doi:10.1207/s15327914nc4402_12 · Cited by 61 · see citing works
Lu, X., Xu, H., Sun, B., Zhu, Z., Zheng, D., & Li, X. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400056c · Cited by 60 · cited 1× · see citing works
“Reduction of the oxidative stress with specific antioxidants has been proved to be effective (Olanow et al., 2004; Lu et al., 2013).”
BackgroundProgress from Alzheimer's tangles to pathological tau points towards more effective therapies now
Lee, V., & Trojanowski, J. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s328 · Cited by 57 · cited 1× · see citing works
“Therefore, drugs with the ability to Frontiers in Pharmacology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 1261 prevent the tau aggregation or block its hyperphosphorylation can be a potential treatment approach (Lee and Trojanowski, 2006; Schneider and Mandelkow, 2008).”
BackgroundFluorinated beta-sheet breaker peptides
Loureiro, J. A., Crespo, R., Börner, H. G., Martins, P. M., Rocha, F. A., Coelho, M. A. N., Pereira, M. D. C., & Rocha, S. (2014) · Journal of Materials Chemistry B · doi:10.1039/c3tb21483d · Cited by 57 · see citing works
Ahn, J. S., Lee, J., Kim, J.-H., & Paik, S. R. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.05.023 · Cited by 57 · cited 2× · see citing works
“Therefore, it is indispensable to find drugs that prevent or inhibit the Aβ aggregation (Ahn et al., 2007; Ramalho et al., 2015b).”
Background
Flagged first, then by citations
3 of the 243 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Potential Adverse Effects of Resveratrol: A Literature Review
Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W. M., Eid, A. H., Nasrallah, G. K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062084 · Cited by 716 · see citing works
Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics
Sharifi‐Rad, M., Lankatillake, C., Dias, D. A., Docea, A. O., Mahomoodally, M. F., Lobine, D., Chazot, P. L., Kurt, B., Tumer, T. B., Moreira, A. C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041061 · Cited by 260 · see citing works
“Therefore, it has the potential also of reducing the pathology of PD or HD, through similar mechanisms [90,91].”
BackgroundAndrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240 · see citing works
“(Vitaceae)) and red wine and its structural formula is presented in Figure 8 [120].”
BackgroundLi, Q., Li, Q.-Q., Jia, J.-N., Sun, Q., Zhou, H., Jin, W., & Mao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00638 · Cited by 154 · see citing works
Kung, H., Lin, K.-J., Kung, C., & Lin, T. (2021) · Biomedicines · doi:10.3390/biomedicines9080918 · Cited by 160 · see citing works
“The chemical has a short biological half-life and is quickly metabolized upon entering the body, which may limit the resveratrol’s scavenging of ROS [209].”
BackgroundRole of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141 · see citing works
Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It?
Salla, M., Karaki, N., Kaderi, B. E., Ayoub, A. J., Younes, S., Chahla, M. N. A., Baksh, S., & Khatib, S. E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040569 · Cited by 110 · see citing works
“This action is believed to be related to neuronal protection against oxidative damage and toxicity and to prevention of apoptotic neuronal death [27].”
BackgroundZhao, M., Li, J.-Q., Chen, F., Dong, W., Wen, L., Fei, W., Zhang, X., Yang, P.-L., Zhang, X., & Zheng, C. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s224579 · Cited by 102 · see citing works
Enhancement of blood–brain barrier penetration and the neuroprotective effect of resveratrol
Katila, N., Duwa, R., Bhurtel, S., Khanal, S., Maharjan, S., Jeong, J., Lee, S., Choi, D., & Yook, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.003 · Cited by 95 · see citing works
Labban, S., Alghamdi, B. S., Alshehri, F. S., & Kurdi, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113100 · Cited by 92 · see citing works
Research Progress on Alzheimer's Disease and Resveratrol
Yan, Y., Yang, H., Xie, Y., Ding, Y., Kong, D., & Yu, H. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03007-0 · Cited by 91 · see citing works
The Plant-Derived Compound Resveratrol in Brain Cancer: A Review
Kisková, T., Kubatka, P., Büsselberg, D., & Kassayová, M. (2020) · Biomolecules · doi:10.3390/biom10010161 · Cited by 92 · see citing works
“RES has been further studied for its increasing relevance in various neurological disorders, such as Alzheimer’s [86–88], Parkinson’s [89,90], and other neurodegenerative diseases [91,92], as well as brain tumors [93–95].”
BackgroundPhytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism
Limanaqi, F., Biagioni, F., Busceti, C. L., Ryskalin, L., Polzella, M., Frati, A., & Fornai, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133274 · Cited by 86 · see citing works
“This may be due to suboptimal phytochemical dosage, timing, or formulation, which may affect phytochemical bioavailability and accumulation in the brain at necessary concentrations for producing evident therapeutic effects [9,17,18].”
BackgroundFarhan, M., & Rizvi, A. (2023) · Nutrients · doi:10.3390/nu15204486 · Cited by 85 · see citing works
Kotta, S., Aldawsari, H. M., Badr-Eldin, S. M., Alhakamy, N. A., & Md, S. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.129721 · Cited by 80 · see citing works
Yadav, E., Yadav, P. S., Khan, M. M. U., Singh, H., & Verma, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.922232 · Cited by 81 · see citing works
Çiftçi, F., Özarslan, A. C., Kantarci, İ. C., Yelkenci, A., Tavukçuoğlu, Ö., & Ghorbanpour, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010121 · Cited by 79 · see citing works
Flavonoids in adipose tissue inflammation and atherosclerosis: one arrow, two targets
Fardoun, M., Maaliki, D. S., Halabi, N., Iratni, R., Bitto, A., Baydoun, E., & Eid, A. H. (2020) · Clinical Science · doi:10.1042/cs20200356 · Cited by 76 · see citing works
Piccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73 · see citing works
Pujara, N., Wong, K. Y., Qu, Z., Wang, R., Moniruzzaman, M., Rewatkar, P. V., Kumeria, T., Ross, B. P., McGuckin, M. A., & Popat, A. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00048 · Cited by 72 · see citing works
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75 · see citing works
“This molecule with neurological benefits is a non-flavonoid polyphenol found in grapes and red wine [53].”
BackgroundYang, S.-Y., Sun, M., & Zhang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921003 · Cited by 67 · see citing works
Nayab, D. E., Din, F. U., Ali, H., Kausar, W. A., Urooj, S., Zafar, M., Khan, I., Shabbir, K., & Khan, G. M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02250-1 · Cited by 68 · see citing works
Natural products for the treatment of neurodegenerative diseases
Cui, D., Chen, Y., Ye, B., Guo, W., Wang, D., & He, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155101 · Cited by 63 · see citing works
Kotta, S., Aldawsari, H., Badr-Eldin, S., Nair, A. B., Kaleem, M., & Dalhat, M. (2022) · Gels · doi:10.3390/gels8070450 · Cited by 52 · see citing works
Ali, M. U., Benfante, V., Raimondo, D. D., Salvaggio, G., Tuttolomondo, A., & Comelli, A. (2024) · Pharmaceuticals · doi:10.3390/ph17010126 · Cited by 58 · see citing works
Resveratrol inhibits inflammation after spinal cord injury via SIRT-1/NF-κB signaling pathway
Zhao, H., Mei, X., Yang, D., & Tu, G. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136151 · Cited by 57 · see citing works
Polyphenols: Natural compounds with promising potential in treating polycystic ovary syndrome
Mihanfar, A., Nouri, M., Roshangar, L., & Ansari, M. H. K. (2021) · Reproductive Biology · doi:10.1016/j.repbio.2021.100500 · Cited by 56 · see citing works
Li, F., Zhan, C., Dong, X., & Wei, G. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01913a · Cited by 54 · see citing works
Jurcău, A. (2021) · Nutrients · doi:10.3390/nu13020282 · Cited by 55 · see citing works
Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders
Singh, A. A., Katiyar, S., & Song, M. (2025) · Brain Sciences · doi:10.3390/brainsci15030252 · Cited by 53 · see citing works
“To overcome these constraints, RES can be given by nanocarriers [207].”
McMeekin, L. J., Fox, S. N., Boas, S. M., & Cowell, R. M. (2021) · Cells · doi:10.3390/cells10020352 · Cited by 51 · see citing works
Kim, Y., Hwang, S., Khalmuratova, R., Kang, S., Lee, M., Song, Y., Park, J., Yu, J., Shin, H., & Lee, Y. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.034 · Cited by 51 · see citing works
Ramalho, M. J., Andrade, S., Coelho, M. A. N., Loureiro, J. A., & Pereira, M. D. C. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.01.015 · Cited by 47 · see citing works
Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies
Kumar, D., Ambasta, R. K., & Kumar, P. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101078 · Cited by 49 · see citing works
Resveratrol-biopolymer materials: A sustainable approach to food packaging
Bahramian, B., Abedi‐Firoozjah, R., Ebrahimi, A., Tavassoli, M., Ehsani, A., & Naebe, M. (2024) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2024.104761 · Cited by 47 · see citing works
Fonseca‐Santos, B., & Chorilli, M. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119832 · Cited by 46 · see citing works
Mokhtari, T. (2022) · Phytotherapy Research · doi:10.1002/ptr.7551 · Cited by 44 · see citing works
Resveratrol as a Therapeutic Agent in Alzheimer’s Disease: Evidence from Clinical Studies
Puranik, N., Kumari, M., Tiwari, S., Dhakal, T., & Song, M. (2025) · Nutrients · doi:10.3390/nu17152557 · Cited by 47 · see citing works
“These advances in nanomedicine may overcome the limitations of RSV, improving its efficacy for treating neurological diseases [118].”
Pogačnik, L., Ota, A., & Ulrih, N. P. (2020) · Cells · doi:10.3390/cells9030576 · Cited by 43 · see citing works
Plasmalogen Replacement Therapy
Bozelli, J. C., & Epand, R. M. (2021) · Membranes · doi:10.3390/membranes11110838 · Cited by 42 · see citing works
Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Jha, N. K., Jha, N. K., Nuli, M. V., Gupta, S. K., Kanna, S., Gahtani, R. M., Hani, U., Singh, A. K., Abomughaid, M. M., Abomughayedh, A. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102224 · Cited by 42 · see citing works
Mitochondrial mechanisms in Cerebral Ischemia-Reperfusion Injury: Unravelling the intricacies
Saini, S. K., & Singh, D. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101883 · Cited by 41 · see citing works
Vasconcelos, T., Araújo, F., Lopes, C., Loureiro, A. I., das Neves, J., Marques, S., & Sarmento, B. F. C. C. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105011 · Cited by 41 · see citing works
Natural Products Targeting Amyloid Beta in Alzheimer’s Disease
Lee, J.-H., Ahn, N.-H., Choi, S.-B., Kwon, Y., & Yang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052341 · Cited by 41 · see citing works
“Resveratrol is also known to suppress the phosphatidylinositol 3-kinase/protein kinase B signaling pathway in addition to having other effects [53,54] that are closely linked to AD, such as the reduction of the amount of Aβ aggregates or Aβ toxicity.”
BackgroundRevisiting the role of mitochondria in spinal muscular atrophy
James, R., Chaytow, H., Ledahawsky, L. M., & Gillingwater, T. H. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03819-5 · Cited by 43 · see citing works
Micale, V., Bartolomeo, M. D., Martino, S. D., Štark, T., Dell’Osso, B. M., Drago, F., & D’Addario, C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108279 · Cited by 40 · see citing works
Resveratrol in Autism Spectrum Disorders: Behavioral and Molecular Effects
Malaguarnera, M., Khan, H. Z., & Cauli, O. (2020) · Antioxidants · doi:10.3390/antiox9030188 · Cited by 38 · see citing works
Fakhri, S., Piri, S., Moradi, S. Z., & Khan, H. Z. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210809103346 · Cited by 39 · see citing works
“MMP-9 is one of the most important members of the MMP family, which has an essential role in neuroinflammation via the activation of several cytokines and chemokines [123-125].”
Rassu, G., Sorrenti, M., Catenacci, L., Pavan, B., Ferraro, L., Gavini, E., Bonferoni, M. C., Giunchedi, P., & Dalpiaz, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061578 · Cited by 36 · see citing works
Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation
Han, Y.-L., Yin, H., Chao, X., Bernards, M. T., He, Y., & Guan, Y. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00586 · Cited by 35 · see citing works
Liposomes: Novel Drug Delivery Approach for Targeting Parkinson’s Disease
Kumar, B., Pandey, M., Pottoo, F. H., Fayaz, F., Sharma, A., & Sahoo, P. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200128145124 · Cited by 32 · see citing works
Andrade, S., Ramalho, M., Loureiro, J., & Pereira, M. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.04.019 · Cited by 30 · see citing works
Katekar, R. A., Thombre, G., Riyazuddin, M., Husain, A., Rani, H., Praveena, K. S., & Gayen, J. R. (2019) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1680690 · Cited by 31 · see citing works
“Anticancer activity of T-RES in leukemia cells and against glioma tumors has already reported (Andrade et al. 2018).”
BackgroundChiang, M., Nicol, C. J. B., Lo, S.-S., Hung, S.-W., Wang, C.-J., & Lin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911678 · Cited by 31 · see citing works
“Resveratrol is a naturally occurring polyphenolic compound found in many plants, such as grapes and blueberries, capable of crossing the blood-brain barrier (BBB) [22,23].”
BackgroundRiccio, B. V. F., Spósito, L., Carvalho, G. C., Ferrari, P. C., & Chorilli, M. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000146 · Cited by 30 · see citing works
Saad, N. M., Sekar, M., Gan, S. H., Lum, P. T., Vaijanathappa, J., & Ravi, S. (2020) · Pharmacognosy Journal · doi:10.5530/pj.2020.12.240 · Cited by 30 · see citing works
Wu, Q., Karthivashan, G., Nakhaei‐Nejad, M., Anand, B. G., Giuliani, F., & Kar, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.08.148 · Cited by 30 · see citing works
Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders
Bicker, J., Fortuna, A. C., Alves, G., & Falcão, A. C. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115101544 · Cited by 30 · see citing works
Kamath, A. P., Nayak, P. G., John, J., Mutalik, S., Balaraman, A. K., & Nandakumar, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110096 · Cited by 29 · see citing works
“Researchers have shown that RSV exhibits numerous beneficial properties for AD, which can be further enhanced by NPs (Table 4) (Andrade et al., 2018; Ashafaq et al., 2021; Dayar and Pechanova, 2021;”
BackgroundWang, Y., Wang, K., Yan, J., Zhou, Q., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213886 · Cited by 29 · see citing works
Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors
Guo, X., Liu, Z., Zheng, Y., Li, Y., Li, L., Liu, H., Chen, Z., & Wu, L. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s237252 · Cited by 27 · see citing works
Socała, K., Żmudzka, E., Lustyk, K., Zagaja, M., Brighenti, V., Costa, A., Andres-Mach, M., Pytka, K., Martinelli, I., Mandrioli, J., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8101 · Cited by 24 · see citing works
Chen, G., Su, Y. A., Chen, S., Lin, T., & Lin, X. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70496 · Cited by 31 · see citing works
“In contrast, resveratrol demonstrates better brain penetration but may require higher doses to achieve therapeutic effects (Andrade et al. 2018).”
Kogut, Ł., Puchalski, C., Katryńska, D., & Zaguła, G. (2026) · Nutrients · doi:10.3390/nu18020313 · Cited by 24 · see citing works
“…come from preclinical studies and are mainly described in qualitative terms, without systematic analysis of the relationship between the effect and the dose and route of administration of resveratrol [92–94,98 In Alzheimer’s disease, resveratrol exhibits multidimensional neuroprotective effects.”
InfluentialResveratrol can inhibit Notch signaling pathway to improve spinal cord injury
Zhang, S., Botchway, B. O. A., Zhang, Y., & Liu, X. (2019) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2019.01.015 · Cited by 24 · see citing works
Miele, D., Catenacci, L., Sorrenti, M., Rossi, S., Sandri, G., Malavasi, L., Dacarro, G., Ferrari, F., & Bonferoni, M. C. (2019) · Marine Drugs · doi:10.3390/md17090515 · Cited by 23 · see citing works
Panwar, S., Uniyal, P., Kukreti, N., Hashmi, A., Verma, S., Arya, A., & Joshi, G. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14515 · Cited by 23 · see citing works
“The natural polyphenolic stilbene derivative, Resveratrol, plays a role in neurodegenerative disorders and stimulates AMPK (AMP-activated protein kinase) and autophagy pathway (Andrade et al., 2018).”
BackgroundNanobiotechnology in Neurodegenerative Diseases
Jampílek, J., Kráľová, K., Novák, P., & Novák, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_4 · Cited by 22 · see citing works
Gao, C., Yang, Z., Song, R., Sheng, H., & Zhu, L. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125375 · Cited by 21 · see citing works
Mohammadi, S., Moghadam, M. D., Nasiriasl, M., Akhzari, M., & Barazesh, M. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328268507231218051058 · Cited by 22 · see citing works
Hidema, S., Kikuchi, S., Takata, R., Yanai, T., Shimomura, K., Horie, K., & Nishimori, K. (2020) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2020.1794783 · Cited by 21 · see citing works
Has resveratrol a potential for mucopolysaccharidosis treatment?
Rintz, E., Pierzynowska, K., Podlacha, M., & Węgrzyn, G. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173534 · Cited by 21 · see citing works
Modulation of cellular redox environment as a novel therapeutic strategy for Parkinson's disease
Deus, C. M., Teixeira, J., Raimundo, N., Tucci, P., Borges, F., Saso, L., & Oliveira, P. J. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13820 · Cited by 21 · see citing works
Samie, S. M. A., & Nasr, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821222-6.00011-7 · Cited by 20 · see citing works
Danışman, B., Kelek, S. E., & Aslan, M. (2023) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2023.23633 · Cited by 19 · see citing works
The Potential Application of Resveratrol and Its Derivatives in Central Nervous System Tumors
Nowacka, A., Śniegocka, M., Smuczyński, W., Liss, S., Ziółkowska, E., Bożiłow, D., Śniegocki, M., & Wiciński, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413338 · Cited by 19 · see citing works
“Neuroprotective properties [81–91]: Resveratrol shows promise as a neuroprotective agent due to its multi-faceted mechanisms of action.”
Ali, S., Khalil, A. A. K., Akhtar, M. S., Amin, A., & Zaman, W. (2025) · ChemistryOpen · doi:10.1002/open.202500469 · Cited by 20 · see citing works
Chinraj, V., & Sureshkumar, R. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120701 · Cited by 19 · see citing works
Zarebavani, M., Naeini, F. B., Farahvash, A., Moradi, F., & Dashti, N. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23311 · Cited by 19 · see citing works
Komorowska, J., Wątroba, M., Bednarzak, M., Grabowska, A. D., & Szukiewicz, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063110 · Cited by 19 · see citing works
“So far, this compound has been encapsulated within a variety of nanosystems, such as liposomes, lipid nanoparticles, and polymeric nanoparticles [111].”
BackgroundElawad, M. A., Ayaz, M., Mosa, O. F., Usman, A., Hamdoon, A. A. E., Almawash, S., Salim, L. H. M., Ahmed, A., & Elkhalifa, M. E. M. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400525 · Cited by 20 · see citing works
Impact of dietary polyphenols on neuroinflammation-associated disorders
Revi, N., & Rengan, A. K. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05303-1 · Cited by 17 · see citing works
“rhodamine B sulfonyl (LissRhod-PE) [75, 76].”
Loureiro, J. A., Ramalho, M. J., & Pereira, M. D. C. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0402 · Cited by 17 · see citing works
Rintz, E., Podlacha, M., Cyske, Z., Pierzynowska, K., Węgrzyn, G., & Gaffke, L. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01323-7 · Cited by 17 · see citing works
“Therefore, various attempts to increase the efficiency of resveratrol delivery to the brain (such as those proposed recently [78, 79]) may be especially important to the development of a true therapy based on this compound.”
BackgroundAbolaji, A. O., Adedara, A. O., Madu, J. C., Owalude, O. T., Ogunyemi, O. M., Omoboyowa, D. A., Omage, F. B., Whitworth, A. J., & Aschner, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-00698-9 · Cited by 15 · see citing works
Effects of lifespan-extending interventions on cognitive healthspan
Čulig, L., Sahbaz, B. D., & Bohr, V. A. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.36 · Cited by 14 · see citing works
Yusof, N. I. S. M., & Fauzi, F. M. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105738 · Cited by 12 · see citing works
Neuroprotective Effects of Resveratrol in Ischemic Brain Injury
Machado, N. D., Armas, G. V., Fernández, M. A., Grijalvo, S., & Díaz, D. D. (2021) · NeuroSci · doi:10.3390/neurosci2030022 · Cited by 12 · see citing works
“This review summarizes the effects of RSV in nerve regeneration after an ischemic brain injury episode (Figure 1), and it is focused on the published results since 2015, complementing various previous revisions [19,20,29].”
ResultKan, S., Liu, C., Zhao, X., Feng, S., Zhu, H., Ma, B., Zhou, M., Fu, X., Hu, W., & Zhu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-46541-x · Cited by 11 · see citing works
Li, J., Li, X., Sun, W. S., Zhang, J., Yan, Q., Wu, J., Jin, J., Lu, R., & Miao, D. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.63876 · Cited by 11 · see citing works
“The poor water solubility, rapid elimination (short half-life) and low bioavailability of resveratrol are the main obstacles to making it useful in clinical trials (35).”
BackgroundZhang, N., Nao, J., & Dong, X. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666241211095018 · Cited by 11 · see citing works
Vengadesan, D., Arumugam, N., Manikandan, E., & Mandal, A. (2024) · BioNanoScience · doi:10.1007/s12668-024-01773-7 · Cited by 10 · see citing works
Evaluation of Resveratrol and Piceatannol Anticonvulsant Potential in Adult Zebrafish (Danio rerio)
Pedroso, J., Schneider, S. E., Lima‐Rezende, C. A., Aguiar, G. P. S., Müller, L. G., de Oliveira, J. V., Piato, Â., & Siebel, A. M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03656-3 · Cited by 10 · see citing works
Advantages and Disadvantages of Nutraceuticals
Ramamoorthy, R., Melians, M. A., Pon, F. F., Cosio, D. S., Buvarahamurthy, V., Jayakumar, A. R., & Paidas, M. J. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-0677-2_15 · Cited by 9 · see citing works
Klein, R. S., Taniguchi, M. M., dos Santos, P. D., Bonafé, E. G., Martins, A. F., & Monteiro, J. P. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114399 · Cited by 9 · see citing works
Advancements in nasal drug delivery system of natural products
Hsu, Y., Yang, J., Cao, M., Xu, T., He, J., Hong, H., Jiang, L., Peng, S., & Xiong, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1667517 · Cited by 8 · see citing works
James, R., Moore, A. L., Carpenter Dick, M., Miller, T. M., & Ledbetter, C. R. (2019) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.1903054 · Cited by 8 · see citing works
“The following is a list of ingredients in the basic supplement panel: Multivitamin [69,70] Omega 3 Fatty Acids 860 mg [71-73] Vitamin K2 45 mcg [74] Vitamin D 11,000 units [75] Probiotic 15 Billion CFU: Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus plantarum plus 15 billion CFU Bifidobacte…”
BackgroundKomorowska, J., Wątroba, M., Bednarzak, M., Grabowska, A. D., & Szukiewicz, D. (2023) · Medical Science Monitor · doi:10.12659/msm.941044 · Cited by 8 · see citing works
“Furthermore, it has been shown that RSV in the CNS can slow progression of Alzheimer disease [78].”
Background
- Authors
- Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A.
- Affiliations
- Universidade do Porto (PT)
- Corresponding author
- Loureiro, Joana A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-20
- Volume
- 9
- Pages
- 1261-1261
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC6262174
- OpenAlex
- W2901539124
- Cited by
- 173
- References
- 243
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 28 · 2023: 16 · 2022: 24 · 2021: 21 · 2020: 26 · 2019: 16
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- Fundação para a Ciência e a Tecnologia (PD/BD/105984/2014, SFRH/BD/129312/2017, NORTE-01-0145-FEDER-000005 – LEPABE-2 ECO-INNOVATION)
- European Regional Development Fund (POCI-01-0145-FEDER-006939, UID/EQU/00511/2013, NORTE-01-0145-FEDER-000005 – LEPABE-2 ECO-INNOVATION)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- resveratrol, brain drug delivery, nanocarriers, blood-brain barrier, neuroprotection, Alzheimer's disease, Parkinson's disease, neurodegenerative diseases, brain cancer, liposomes, polymeric nanoparticles, lipid nanoparticles, drug bioavailability, oxidative stress, apoptosis, angiogenesis inhibition, nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
